A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion

References

• Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10:S98-109; PMID:15577938; http://dx.doi.org/10.1038/nm1144
   PubMed Web of Science ®Google Scholar
• Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-81; PMID:3277268; http://dx.doi.org/10.1126/science.3277268
   PubMed Web of Science ®Google Scholar
• Narvaez F, Gutierrez G, Perez MA, Elizondo D, Nunez A, Balmaseda A, Harris E. Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS Negl Trop Dis 2011; 5:e1397; PMID:22087348; http://dx.doi.org/10.1371/journal.pntd.0001397
   PubMed Web of Science ®Google Scholar
• Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010; 6:e1000790; PMID:20168989; http://dx.doi.org/10.1371/journal.ppat.1000790
   PubMed Web of Science ®Google Scholar
• Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008; 319:1830-4; PMID:18369147; http://dx.doi.org/10.1126/science.1153263
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005; 3:13-22; PMID:15608696; http://dx.doi.org/10.1038/nrmicro1067
   PubMed Web of Science ®Google Scholar
• Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008; 15:312-7; PMID:18264114; http://dx.doi.org/10.1038/nsmb.1382
   PubMed Web of Science ®Google Scholar
• Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11:522-30; PMID:15852016; http://dx.doi.org/10.1038/nm1240
   PubMed Web of Science ®Google Scholar
• Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001; 75:7769-73; PMID:11462053; http://dx.doi.org/10.1128/JVI.75.16.7769-7773.2001
   PubMed Web of Science ®Google Scholar
• Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002; 108:717-25; PMID:11893341; http://dx.doi.org/10.1016/S0092-8674(02)00660-8
   PubMed Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004; 427:313-9; PMID:14737159; http://dx.doi.org/10.1038/nature02165
   PubMed Web of Science ®Google Scholar
• Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, Yang HO, Tan WL, Liu R, Yu M, Ge BX, et al. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One 2011; 6:e16059; PMID:21264311; http://dx.doi.org/10.1371/journal.pone.0016059
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 2001; 951:286-97; PMID:11797785; http://dx.doi.org/10.1111/j.1749-6632.2001.tb02704.x
   PubMed Web of Science ®Google Scholar
• Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003; 77:12941-9; PMID:14645550; http://dx.doi.org/10.1128/JVI.77.24.12941-12949.2003
   PubMed Web of Science ®Google Scholar
• Morrey JD, Siddharthan V, Olsen AL, Roper GY, Wang H, Baldwin TJ, Koenig S, Johnson S, Nordstrom JL, Diamond MS. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 2006; 194:1300-8; PMID:17041857; http://dx.doi.org/10.1086/508293
   PubMed Web of Science ®Google Scholar
• Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shochat SG, Sukupolvi-Petty S, Schul W, Diamond MS, Vasudevan SG, Lescar J. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 2009; 90:799-809; PMID:19264660; http://dx.doi.org/10.1099/vir.0.006874-0
   PubMed Web of Science ®Google Scholar
• Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002; 99:11346-50; PMID:12177434; http://dx.doi.org/10.1073/pnas.172229899
   PubMed Web of Science ®Google Scholar
• Tan W, Meng Y, Li H, Chen Y, Han S, Zeng J, Huang A, Li B, Zhang Y, Guo Y. A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity. MAbs. 2013; 5:946-55; PMID:24492346; http://dx.doi.org/10.4161/mabs.26390
   PubMed Web of Science ®Google Scholar
• Arndt M, Krauss J. Bispecific diabodies for cancer therapy. Methods Mol Biol 2003; 207:305-21; PMID:12412482
   PubMedGoogle Scholar
• Peipp M, Valerius T. Bispecific antibodies targeting cancer cells. Biochem Soc Trans 2002; 30:507-11; PMID:12196124; http://dx.doi.org/10.1042/bst0300507
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
   PubMed Web of Science ®Google Scholar
• Kou G, Shi J, Chen L, Zhang D, Hou S, Zhao L, Fang C, Zheng L, Zhang X, Liang P, et al. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett 2010; 299:130-6; PMID:20826049; http://dx.doi.org/10.1016/j.canlet.2010.08.011
   PubMed Web of Science ®Google Scholar
• Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005; 437:764-9; PMID:16193056; http://dx.doi.org/10.1038/nature03956
   PubMed Web of Science ®Google Scholar
• Thompson BS, Moesker B, Smit JM, Wilschut J, Diamond MS, Fremont DH. A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog 2009; 5:e1000453; PMID:19478866; http://dx.doi.org/10.1371/journal.ppat.1000453
   PubMed Web of Science ®Google Scholar
• Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421-67; PMID:14689700; http://dx.doi.org/10.1016/S0065-3527(03)60011-4
   PubMed Web of Science ®Google Scholar
• Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 2004; 189:1411-8; PMID:15073678; http://dx.doi.org/10.1086/383043
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA,et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9; PMID:10608744; http://dx.doi.org/10.1086/315215
   PubMed Web of Science ®Google Scholar
• Murgue B, Roche C, Chungue E, Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000; 60:432-8; PMID:10686027; http://dx.doi.org/10.1002/(SICI)1096-9071(200004)60:4%3c432::AID-JMV11%3e3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, Nimmannitya S, Soegijanto S, Vaughn DW, Endy TP. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 2002; 8:1474-9; PMID:12498666; http://dx.doi.org/10.3201/eid0812.020170
   PubMed Web of Science ®Google Scholar
• Li B, Meng Y, Zheng L, Zhang X, Tong Q, Tan W, Hu S, Li H, Chen Y, Song J, et al. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res. 2013; 73:6471-83; PMID:24046294; http://dx.doi.org/10.1158/0008-5472.CAN-13-0657
   PubMed Web of Science ®Google Scholar
• Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, Witte L, Zhu Z. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 1999; 230:159-71; PMID:10594363; http://dx.doi.org/10.1016/S0022-1759(99)00135-0
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 2008; 375:287-91; PMID:18680722; http://dx.doi.org/10.1016/j.bbrc.2008.07.121
   PubMed Web of Science ®Google Scholar
• Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008; 319:1830-4; PMID:18369147; http://dx.doi.org/10.1126/science.1153263
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005; 3:13-22; PMID:15608696; http://dx.doi.org/10.1038/nrmicro1067
   PubMed Web of Science ®Google Scholar
• Dai J, Li B, Shi J, Peng L, Zhang D, Qian W, Hou S, Zhao L, Gao J, Cao Z, et al. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 2010; 59:355-66; PMID:19690854; http://dx.doi.org/10.1007/s00262-009-0754-z
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 2007; 366:349-60; PMID:17719070; http://dx.doi.org/10.1016/j.virol.2007.05.042
   PubMed Web of Science ®Google Scholar
• Matsui K, Gromowski GD, Li L, Schuh AJ, Lee JC, Barrett AD. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 2009; 384:16-20; PMID:19101005; http://dx.doi.org/10.1016/j.virol.2008.11.013
   PubMed Web of Science ®Google Scholar